Breakthrough Mineralocorticoid Receptor Agonists in Cardiovascular Care
In this expert-led webinar moderated by Dr Vijay Chopra, leading clinicians review current and emerging strategies in aldosterone modulation, hyperkalaemia management, and cardiorenal therapeutics.
Dr Javed Butler opens with a practical overview of aldosterone’s central role in heart failure and CKD, emphasising the importance of achieving guideline-directed RAAS inhibitor and MRA dosing. He outlines real-world barriers posed by hyperkalaemia and provides clear strategies to maintain life-saving therapy safely, including the use of modern potassium binders.
Dr Dinesh Khullar presents the clinical evidence for finerenone, a non-steroidal MRA with improved selectivity and a lower risk of hyperkalaemia. He summarises key findings from FIDELITY, CONFIDENCE, and FINEARTS-HF, demonstrating meaningful reductions in CKD progression, heart failure events, albuminuria, and cardiovascular risk, particularly when combined with SGLT2 inhibitors.
Prof John McMurray explores the future of aldosterone-targeted therapy with aldosterone synthase inhibitors (ASIs). He reviews promising hypertension data for agents such as baxdrostat and outlines large-scale ongoing trials investigating ASIs in HFrEF, HFpEF, CKD, and heart failure prevention, pointing toward a major shift in proactive cardiorenal care.
The session concludes with a dynamic panel discussion addressing potassium thresholds, binder selection, chronic vs acute hyperkalaemia tolerance, insights from the PODCAST trial, and the scientific rationale behind combining MRAs and ASIs.
Overall, this webinar offers a concise, clinically relevant look at today’s best practices and tomorrow’s innovations in cardiorenal medicine.
For more on emerging strategies in aldosterone inhibition, read Cardiac Failure Review Journal’s Special Focus Issue on “New Mineralocorticoid Receptor Antagonists/Aldosterone Antagonists”.
Key Learning Objectives
- Identify clinical barriers associated with traditional aldosterone management and recognize the impact of hyperkalemia on patient outcomes and treatment adherence
- Evaluate the clinical evidence supporting non-steroidal MRAs, particularly finerenone, and understand their role in modern cardiovascular therapeutic strategies
- Apply practical strategies for implementing breakthrough MRA therapies while managing potassium levels and optimizing patient safety profiles
- Distinguish between different approaches to mineralocorticoid pathway modulation, including receptor antagonism and aldosterone synthesis inhibition
- Integrate evidence-based protocols for MRA therapy selection and monitoring in patients with hypertension and heart failure
- Assess patient-specific factors that influence MRA therapy choice and develop personalized treatment approaches for diverse cardiovascular populations
Target Audience
- Cardiologists and interventional cardiologists managing heart failure and hypertensive patients
- Clinical pharmacologists specializing in cardiovascular therapeutics
- Heart failure specialists and advanced heart failure practitioners
- Cardiovascular medicine fellows and cardiology residents
- Nephrology specialists managing patients with cardiovascular comorbidities
More from this programme
Part 1
Breakthrough Mineralocorticoid Receptor Agonists in Cardiovascular Care
In this expert-led webinar moderated by Dr Vijay Chopra, leading clinicians review current and emerging strategies in aldosterone modulation, hyperkalaemia management, and cardiorenal therapeutics.
Dr Javed Butler opens with a practical overview of aldosterone’s central role in heart failure and CKD, emphasising the importance of achieving guideline-directed RAAS inhibitor and MRA dosing. He outlines real-world barriers posed by hyperkalaemia and provides clear strategies to maintain life-saving therapy safely, including the use of modern potassium binders.
Dr Dinesh Khullar presents the clinical evidence for finerenone, a non-steroidal MRA with improved selectivity and a lower risk of hyperkalaemia. He summarises key findings from FIDELITY, CONFIDENCE, and FINEARTS-HF, demonstrating meaningful reductions in CKD progression, heart failure events, albuminuria, and cardiovascular risk, particularly when combined with SGLT2 inhibitors.
Prof John McMurray explores the future of aldosterone-targeted therapy with aldosterone synthase inhibitors (ASIs). He reviews promising hypertension data for agents such as baxdrostat and outlines large-scale ongoing trials investigating ASIs in HFrEF, HFpEF, CKD, and heart failure prevention, pointing toward a major shift in proactive cardiorenal care.
The session concludes with a dynamic panel discussion addressing potassium thresholds, binder selection, chronic vs acute hyperkalaemia tolerance, insights from the PODCAST trial, and the scientific rationale behind combining MRAs and ASIs.
Overall, this webinar offers a concise, clinically relevant look at today’s best practices and tomorrow’s innovations in cardiorenal medicine.
Faculty Biographies
Vijay Chopra
Senior Director of Clinical Cardiology, Heart Failure and Research
Dr Vijay Chopra is the Senior Director of Clinical Cardiology, Heart Failure and Research in the Heart Failure Programme at the Max Super Specialty Hospital in Saket, New Delhi, India. He is considered a pioneer in preventive cardiology, and has worked extensively in the management of patients with advanced heart disease. He has been principal investigator of numerous international clinical trials.
Dr Chopra's research interests include preventive cardiology, heart failures and advanced heart diseases. He was awarded the Kutumbiah Prize in Clinical Medicine from CMC Vellore in 1972. He founded the Heart Failure Association of India (HFAI), and served as its first president from 2014 - 2019.
Dr Chopra has over 50 publications in peer-reviewed journals.
Dr Vijay Chopra is an Editorial Board member of Cardiac Failure Review and may be contacted
Comments